{
    "nctId": "NCT02843126",
    "briefTitle": "Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer",
    "officialTitle": "N/A",
    "overallStatus": "COMPLETED",
    "conditions": "Recurrent Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Relief degree evaluated by the RECIST",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence\n* Body tumor 1-6, the maximum tumor length \\< 5 cm\n* KPS \u2265 70, lifespan \\> 6 months\n* Platelet count \u2265 80\u00d7109/L\uff0cwhite blood cell count \u2265 3\u00d7109/L, neutrophil count \u2265 2\u00d7109/L, hemoglobin \u2265 80 g/L\n\nExclusion Criteria:\n\n* Patients with cardiac pacemaker\n* Patients with brain metastasis\n* Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}